Rogerio C. Lilenbaum, MD

Professor of Medicine (Medical Oncology); Chief Medical Officer of Smilow Cancer Hospital

Physician Biography

Dr. Lilenbaum received his medical degree from the Federal University of Rio de Janeiro School of Medicine in Brazil and earned a masters degree in clinical epidemiology and clinical investigation from the Harvard School of Public Health. He completed his hematology/oncology fellowship at Washington University School of Medicine and a clinical and research fellowship at the University of California San Diego.

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Medical Oncology: Subset Medical Oncology Faculty

Cancer Center: Thoracic Oncology Program

Yale Medical Group

Office of Cooperative Research

Board Certifications

  • Medical Oncology AB of Internal Medicine (1997)

  • Hematology (Internal Medicine) AB of Internal Medicine (1998)

Clinical Trials

Conditions Study Title
Lung Phase 2 Study of LY2606368 in Patients with Extensive Stage Disease Small Cell Lung Cancer
Lung A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Cou
Lung A081105: Erlotinib Hydrochloride in Patients w/Stage IB-IIIA NSCLC That Has Been Removed Surgically
Lung E4512: Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been R
Lung A151216:Genetic Testing in Screening Patients w/Stage IB-IIIA NSCLC That Has Been or Will Be Removed
Lung Phase 3 study MPDL3290A with Cisplatin or Carboplatin+Pemetrexed for PD-L1- Stage 4 NSCLC
Lung Phase 3, MPDL3280A with Carboplatin+Paclitaxel or Carboplatin+Paclitaxel+Bevacizumab in NSCLC
Brain and Nervous System, Lung, Melanoma, skin Pembrolizumab and bevacizumab in untreated brain metastases
Lung Phase 3 - Nivo, or Nivo+Ipilmumab vs. platinum doublet chemo in chemotherapy-naive stage 4 or NSCLC
Lung Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent NSCLC
Lung CheckMate 331: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 331
Bladder, Lung, Other Digestive Organ, Other Urinary, Stomach, Phase I Ramucirumab + Pembro with Gastric or GEJ Adenocarcinoma, NSCLC or Tcell carcinoma of urothelium
Lung A randomized phase II trial of combination versus single agent chemotherapy in high-risk elderly pat
Lung S1403
Lung PINNACLE: Phase 1b/2 Study of Anti-Notch Antibody Therapy with Cisplatin and Etoposide in SCLC
Lung, Melanoma, skin Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic
Lung, Phase I A Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB o
Lung Safety and Efficacy of Abraxane Maintenance post Abraxane + Carboplatin in squamous cell lung cancer
Lung Biomarker-Driven Master Protocol for Squamous Cell Lung Cancer
Lung, Melanoma, skin Phase 2 Study of MK-3475 in Patients with Melanoma or NSCLC with Untreated Brain Mets

Edit this profile

Contact Info

Rogerio C. Lilenbaum, MD
Patient Care Location
Smilow Cancer Hospital at Yale-New HavenSmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste North Pavilion 4

New Haven, CT 06511
View on map...
Mailing Address
20 York Street
New Haven, CT 06520-8021